Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xevinapant in recurrent high-grade glioma
NCT06463184Phase 1Withdrawn
- Sponsor
- Moffitt Cancer Center
- Start
- Jul 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of xevinapant in glioma, sponsored by Moffitt Cancer Center. Primary endpoints: Concentration of Xevinapant and Maximum Concentration. Planned start Jul 2024; status: withdrawn.
02
Drugs
xevinapant
03
Conditions
glioma
Beyond the preview
Go deeper on NCT06463184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06463184.